US EditionEli Lilly Expects to Have the Clinical Results of His New Weight Loss in 3Q25: a Weight Loss of 8% in 40 Weeks vs 6% of a Similar Novo Nordisk Drug
Summary by Consenso Del Mercado
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Bankinter Market Consensus The pharmaceutical company is burdened by the decision of the British health system not to subsidize its medicine for Alzheimer's. Although, during the weekend we have had positive news, and is that the company expects to have the clinical results of its new slimming in 3Q 2025. It is a new slimming pill based on the active principle orforglipron whose results presented them at the recent annual congress of the Americ…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
